Trial · NCT07906145
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and Tolerability of QLS2416 Injection | Up to 24 weeks | Incidence and severity of treatment-emergent adverse events. |
| Secondary | Pharmacokinetic Profile of QLS2416 | Up to 24 weeks | Peak Plasma Concertration(Cmax) |
| Secondary | Pharmacokinetic Profile of QLS2416 | Up to 24 weeks | Time to maximum plasma concentration(Tmax) |
| Secondary | Pharmacokinetic Profile of QLS2416 | Up to 24 weeks | Elimination half-life (t1/2) |
| Secondary | Anti-Drug Antibody | Up to 24 weeks | Incidence of anti-QLS2416 antibodies (ADA) |
| Secondary | SLE Responder Index (SRI) and Other SLE Disease Activity Measures | Up to 24 weeks | Percentage of participants achieving SRI (4) |
| Secondary | SLE Responder Index (SRI) and Other SLE Disease Activity Measures | Up to 24 weeks | Percentage of participants achieving Definitions Of Remission In Systemic Lupus Erythematosus remission(DORIS remission) |
| Secondary | SLE Responder Index (SRI) and Other SLE Disease Activity Measures | Up to 24 weeks | Percentage of participants achieving Lupus Low Disease Activity State(LLDAS) |
| Secondary | RA Disease Activity Measures | Up to 24 weeks | Changes in Disease Activity Score in 28 Joints - C-reactive Protein (DAS28-CRP). |
| Secondary | pSS Disease Activity Measures | Up to 24 weeks | Changes in Clinical European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (clinESSDAI). |
| Secondary | SSc Disease Activity Measures | Up to 52 weeks | Changes in modified Rodnan skin score (mRSS). |
| Secondary | SSc Disease Activity Measures | Up to 52 weeks | Changes in Combined Response Index for Systemic Sclerosis(CRISS). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07906145/registered